Odizat

Active Ingredients & Mechanisms of Action

1. Amlodipine (CCB): A dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and cardiac cells. This promotes direct arterial relaxation and vasodilation, reducing total peripheral vascular resistance.
2. Valsartan (ARB): An angiotensin II receptor blocker that selectively prevents angiotensin II from binding to $\text{AT}_1$ receptors in vascular smooth muscle and adrenal glands. This blocks vasoconstriction and halts aldosterone release, reducing total fluid retention and vascular tightness.
3. Hydrochlorothiazide (Thiazide Diuretic — in Odizat HCT): Increases the renal excretion of sodium, chloride, and accompanying fluid through the kidneys, decreasing overall intravascular fluid volume and cardiac workload.

Common Dosage Formulations & Strengths

• Odizat (Dual Combination):
  • 5 mg / 160 mg: 5 mg Amlodipine + 160 mg Valsartan
  • 10 mg / 160 mg: 10 mg Amlodipine + 160 mg Valsartan
• Odizat HCT (Triple Combination):
  • 10 mg / 160 mg / 12.5 mg: 10 mg Amlodipine + 160 mg Valsartan + 12.5 mg Hydrochlorothiazide
  • 10 mg / 160 mg / 25 mg: 10 mg Amlodipine + 160 mg Valsartan + 25 mg Hydrochlorothiazide

Clinical Indications

• Essential Hypertension: Treatment of high blood pressure in patients whose blood pressure is not adequately controlled on single-agent or dual-agent monotherapy.
• Cardiovascular Risk Reduction: Lowering elevated blood pressure to minimize the long-term risk of fatal and non-fatal cardiovascular events, including strokes and myocardial infarctions.

Key Pharmacokinetics

• Absorption: Active ingredients are rapidly absorbed following oral administration. Peak plasma concentration ($C_{max}$) occurs within 2 to 4 hours for valsartan and 6 to 12 hours for amlodipine.
• Duration of Action: The long elimination half-life of amlodipine ($30\text{–}50\text{ hours}$) and high receptor affinity of valsartan provide smooth, continuous 24-hour therapeutic coverage with once-daily dosing.
• Excretion: Valsartan is excreted primarily unchanged via bile and feces; amlodipine is extensively metabolized by the liver; hydrochlorothiazide is excreted unchanged by the kidneys.

Administration Guidelines

• Usage: Administered orally once daily with water, with or without food.
• Consistency: Should be taken at approximately the same time each day to maintain steady therapeutic blood levels.

Safety Profile & Considerations

• Common Side Effects: Peripheral edema (ankle swelling), dizziness, headache, fatigue, flushing, and mild electrolyte imbalances.
• Boxed Warning (Fetal Toxicity): Drugs acting on the renin-angiotensin system (such as valsartan) can cause severe fetal injury and death when administered to pregnant women. Discontinue immediately if pregnancy is detected.
• Contraindications: Known hypersensitivity to amlodipine, valsartan, sulfonamides (for HCT formulations), or other dihydropyridine derivatives. Do not co-administer with aliskiren in patients with diabetes mellitus.
• Key Interactions:
  • Potassium Supplements / Salt Substitutes: Increased risk of hyperkalemia (high blood potassium) due to the ARB component.
  • Lithium: Thiazide diuretics reduce renal clearance of lithium, increasing toxicity risks.
  • NSAIDs: Concomitant use may diminish blood pressure-lowering efficacy and increase the risk of severe renal impairment.

Note: Odizat is a prescription-only medication. Treatment, dose adjustments, and clinical monitoring should strictly follow the guidance of a licensed healthcare professional.